Ozempic, a Diabetes Medication, Slated for India Launch This Month

Novo Nordisk is set to introduce Ozempic in India, complementing their existing semaglutide product line. This launch occurs amidst strong competition from Eli Lilly's Mounjaro. The new medication may also be prescribed for other health conditions.

Diabetes Drug Ozempic Coming to India This Month

Novo Nordisk's semaglutide portfolio in India will be completed with the launch of Ozempic, providing therapeutic options for both diabetes and obesity. This introduction follows increasing competition from Eli Lilly's Mounjaro, a US rival approved for both diabetes and weight management. Pharmarack data indicates that Lilly sold 262,000 doses of Mounjaro in October, compared to Novo's Wegovy with 26,000 doses.

Novo Nordisk already maintains a significant presence in the diabetes market in India through its Rybelsus semaglutide tablets and other offerings. According to Vishal Manchanda, an analyst from Systematix Institutional Equities, "Novo is well-positioned to promote Ozempic due to its established brand recognition in diabetes treatment."

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store

Get it onGoogle Play

Furthermore, Manchanda suggested that "Ozempic may potentially be prescribed for individuals experiencing infertility or sleep apnea, and for those seeking weight reduction." Health tracking apps like Shotlee can help monitor any side effects from new medications.

Source Information

Originally published by NewsBytes.Read the original article →

Keep exploring

More on Ozempic

Articles covering Ozempic dosing, side effects, and clinical updates.

Medical Insights

People Taking GLP-1 Weight Loss Drugs Like Ozempic and Wegovy Started Moving Less

New data presented at ENDO 2026 reveals a paradox: patients on GLP-1 medications like Ozempic and Wegovy reduced their physical activity despite losing weight.

8 min read

Medical Research

Popular Weight-Loss Drugs Ozempic and Wegovy May Slow Biological Aging

A new clinical trial suggests that semaglutide, the active ingredient in Ozempic and Wegovy, may help slow biological processes associated with aging in adults with HIV.

8 min read

Health & Wellness

Yes, GLP-1s Make You Thinner. But Do They Make You Freer?

While GLP-1 drugs like Ozempic and Wegovy offer significant medical benefits, their rise raises critical questions about freedom, body image, and the cultural pressure to be thinner.

8 min read

Same topic: Diabetes

All Diabetes articles →

Health & Wellness

Ozempic and Wegovy Use Linked to Thousands of Poison Control Calls

The widespread adoption of Ozempic and Wegovy for weight loss has coincided with a significant rise in calls to poison control centers. This article delves into the research behind this trend, highlighting common mistakes and the importance of proper patient education.

6 min read

Medication News

New Weight Loss Pill Beats Oral Ozempic in Major Clinical Trial

A recent Phase 3 clinical trial indicates that orforglipron offers superior blood sugar control and weight loss compared to oral semaglutide, though side effects remain a consideration.

9 min read

More in Health

Health

Novo Nordisk India Introduces Ozempic, Considering Socio-Economic Factors | Briefs

Novo Nordisk has officially launched Ozempic in India, a once-weekly GLP-1 receptor agonist for adults managing uncontrolled type 2 diabetes. Intended as an add-on therapy to diet and exercise, Ozempic arrives as India grapples with a rapidly increasing diabetes burden and generalized obesity.

1 min read

Health

Anticipating Large Profits: Ozempic Patent Expiration Sparks Indian Pharma Generics Race

With the impending expiration of the Ozempic and Wegovy patents, Indian pharmaceutical giants are gearing up for a significant opportunity in the generics market. Surging obesity rates across India are fueling the demand for affordable weight-loss solutions.

7 min read

Health

Mounjaro Weight-Loss Injection Now Top-Selling Drug in India

According to recent data, Mounjaro, a drug for obesity and diabetes developed by Eli Lilly, has emerged as India's top-selling pharmaceutical brand. The medication's sales have surpassed those of long-time market leader Augmentin.

3 min read